Yuanshi (Shanghai) Technology Co., Ltd. is a specialist in the realm of AI-powered virtual cells. Leveraging a biological raw data engine and universal cell models, the company is constructing a fundamental platform for the life sciences. Recently, Yuanshi Technology has successfully secured close to 100 million yuan in both angel and angel+ funding rounds. The angel round was co-led by Sinovation Ventures, Shanghai Future Industry Fund, and Yanyuan Venture Capital. Meanwhile, the angel+ round was spearheaded by Monolith, with Daotong Capital also participating. The capital raised will be mainly allocated to model development, the establishment of data and experimental platforms, as well as application validation within drug development contexts. Yuanshi Technology is dedicated to creating a self-evolving universal cell large model and establishing a self-sustaining, closed-loop virtual cell research and development system. This initiative aims to propel AI-driven drug discovery from point-based analysis to high-dimensional prediction. Investors are bullish on the long-term prospects of the virtual cell sector, as well as Yuanshi Technology's technological prowess and team capabilities. They will offer assistance in aligning industrial resources and converting scientific research achievements, thereby aiding the company's technological implementation and commercialization efforts.